JP EN

Introduction of each center/hub/department

Research Divisions

Development of superior cell and DDS for regenerative medicine

Overview

Director

Makiya NISHIKAWAProfessor

Affiliation
Department of Pharmacy Faculty of Pharmaceutical Sciences
RIDAI

Comment

Cell-based therapy and regenerative medicine can be greatly accelerated by applying the concept of drug delivery system (DDS), i.e., drug delivery at the right time, at the right site of action, and in the right amount, to cells that are administered to patients for disease treatment. This division aims at developing “superior cells” whose functions are extremely upregulated and DDS that improves their functions.

Research Content

Development of superior cells and DDS for accelerating regenerative medicine

Objectives

To develop “superior cells” and DDS that can precisely control the function and in vivo fate of the cells for accelerating regenerative medicine.

Future Development Goals

To create a novel and unique research field focusing on “superior cells” by collaboration of researchers with a variety of expertise.

SDGs

Members

Click here for details
Name Job Title Affiliation
Makiya NISHIKAWA Director / Professor Department of Pharmacy,Faculty of Pharmaceutical Sciences
Yoichiro ISOHAMA Professor Department of Pharmacy,Faculty of Pharmaceutical Sciences
Takehisa HANAWA Professor Department of Pharmacy,Faculty of Pharmaceutical Sciences
Chikamasa YAMASHITA  Professor Department of Medicinal and Life Sciences,Faculty of Pharmaceutical Sciences
Satoru GOTO  Professor Department of Pharmacy,Faculty of Pharmaceutical Sciences
Akihiko KIKUCHI Professor Department of Materials Science and Technology,Faculty of Advanced Engineering
Tadayoshi HAYATA  Associate Professor Department of Medicinal and Life Sciences,Faculty of Pharmaceutical Sciences
Yoshitsugu AKIYAMA Associate Professor Institute of Arts and Sciences, Katsushika Division, Institute of Arts and Sciences
Kosuke KUSAMORI Associate Professor Department of Medicinal and Life Sciences,Faculty of Pharmaceutical Sciences
Tomomi AKITA  Junior Associate Professor Department of Medicinal and Life Sciences,Faculty of Pharmaceutical Sciences
Kazuhito MURAKAMI Assistant Professor Department of Pharmacy,Faculty of Pharmaceutical Sciences
Syuuhei KOMATSU Assistant Professor Department of Materials Science and Technology,Faculty of Advanced Engineering

Research Summary

Development of superior cells and DDS for accelerating regenerative medicine

History and Background of This Division

This division has a root in the DDS Research Division established in the Research Institutes for Science and Technology, Tokyo University of Science in 2003. In“ Fusion of Regenerative Medicine with DDS Division” started from 2015, researchers headed by Professor Kimiko Makino have conducted collaborative researches focusing on regenerative medicine and the development of DDS for intractable diseases. To continue these activities, a predecessor round-table conference on Superior Cells and DDS Development for Regenerative Medicine was founded on 2020, which has been reestablished as a division in April 2021.

Research Purposes and Goals of This Division

Under the overall goal of accelerating cell-based therapy and regenerative medicine, this division is focusing on (1) the development of “superior cells” by functionalizing the cells administered to patients for therapeutic purposes, and (2) the development of DDS that can precisely manipulate the in vivo distribution of cells and other functional molecules. The research purposes also include the development of therapeutic modalities against respiratory, brain, immune, cancer, and bone diseases.

Members and Their Roles in This Division

The four groups below cooperate with one another to accelerate the group research.

(1) Superior cell/DDS development group

This group designs and constructs superior cells, and develops DDS aiming at controlling the function and in vivo distribution of cells and other functional bioactive molecules. A goal is to develop “superior cells” that super-exceed the existing cells in terms of cellular functions through (1) the addition of novel functions, (2) the development of multicellular spheroids/organoids, and (3) the use of exosomes and other extracellular vesicles. In addition, various delivery systems are developed and applied to the superior cells and their usefulness is examined in animal models.

(2) Cell function regulation system development group

This group creates novel compounds that regulate cellular functions, and functional materials that can be used in cell-based therapy and regenerative medicine. These compounds and materials are supplied to other groups for applications and analysis. The data obtained using them are used for the development of more functional compounds/materials.

(3) Physical property control/analysis group

This group evaluates the physical properties of the items developed by the superior cell/DDS development group and the cell function regulation system development group, including superior cells, delivery systems, and functional compounds/materials. This group supports the optimization of these items by data feedback to the corresponding groups.

(4) Cell/tissue regeneration group

This group investigates the mechanisms of the regeneration of the lung, bone and other tissues, and treat the diseases of these tissues/organs. The interaction of superior cells/DDS and the immune systems is also analyzed.

Fig.1 Members and roles of each group.